(ELVN) Enliven Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.573m USD | Total Return: 147.7% in 12m
Avg Turnover: 25.1M
Warnings
Share dilution 25.5% YoY
High Debt while negative Cash Flow
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader
Enliven Therapeutics Inc. (ELVN) is a Boulder-based biopharmaceutical firm specializing in the discovery of small molecule inhibitors for oncology. The company’s pipeline currently features two Phase 1 clinical programs: ELVN-001, targeting chronic myeloid leukemia, and ELVN-002, a CNS-penetrant inhibitor designed for HER2-mutant lung cancer and other solid tumors.
Operating within the biotechnology sector, Enliven utilizes a research-intensive business model that prioritizes high selectivity and brain penetration to overcome common resistance mechanisms in cancer therapy. Unlike traditional pharmaceutical companies with established revenue streams, clinical-stage firms typically rely on milestone-driven venture funding or equity offerings to finance the multi-year drug approval process.
Investors may find additional valuation metrics and peer comparisons by exploring ValueRay. Founded in 2019, the company focuses on addressing unmet medical needs through precision oncology, a field characterized by high R&D expenditures and significant regulatory oversight.
- ELVN-001 Phase 1 clinical trial data readouts drive oncology investor sentiment
- Regulatory progress for ELVN-002 CNS penetrant impacts lung cancer market valuation
- R&D expenditure and cash runway determine timeline for future clinical milestones
- Competitive landscape for CML small molecule inhibitors affects long term market share
- FDA approval pathways for HER2 mutant tumor treatments dictate regulatory risk profile
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA 10.35 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.14 > 3% & CFO -65.5m > Net Income -98.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 40.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.8m) vs 12m ago 25.47% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.10%; Δ -0.10% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.97 (Total Current Assets 463.1m - Total Current Liabilities 11.5m) / Total Assets 464.9m |
| B: -0.80 (Retained Earnings -370.8m / Total Assets 464.9m) |
| C: -0.29 (EBIT TTM -110.9m / Avg Total Assets 383.7m) |
| D: -32.31 (Book Value of Equity -371.1m / Total Liabilities 11.5m) |
| Altman-Z'' = -32.09 = D |
As of May 24, 2026, the stock is trading at USD 42.25 with a total of 918,334 shares traded.
Over the past week, the price has changed by +0.48%,
over one month by -6.53%,
over three months by +51.33% and
over the past year by +147.70%.
Enliven Therapeutics has received a consensus analysts rating of 4.88. Therefore, it is recommended to buy ELVN.
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 57 | 34.9% |
Revenue TTM = 0.0 USD
EBIT TTM = -110.9m USD
EBITDA TTM = -110.7m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 302k USD (from shortTermDebt, last quarter)
Debt = 302k USD (from shortLongTermDebtTotal, last quarter) (leases 302k already included)
Net Debt = -452.1m USD (calculated: Debt 302k - CCE 452.4m)
Enterprise Value = 2.12b USD (2.57b + Debt 302k - CCE 452.4m)
Interest Coverage Ratio = unknown (Ebit TTM -110.9m / Interest Expense TTM 0.0)
EV/FCF = -32.33x (Enterprise Value 2.12b / FCF TTM -65.6m)
FCF Yield = -3.09% (FCF TTM -65.6m / Enterprise Value 2.12b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 263k) / Revenue TTM)
Tobins Q-Ratio = 4.56 (Enterprise Value 2.12b / Total Assets 464.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 302k)
Taxrate = 21.0% (US default 21%)
NOPAT = -87.6m (EBIT -110.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 40.32 (Total Current Assets 463.1m / Total Current Liabilities 11.5m)
Debt / Equity = 0.00 (Debt 302k / totalStockholderEquity, last quarter 453.4m)
Debt / EBITDA = 4.09 (negative EBITDA) (Net Debt -452.1m / EBITDA -110.7m)
Debt / FCF = 6.89 (negative FCF - burning cash) (Net Debt -452.1m / FCF TTM -65.6m)
Total Stockholder Equity = 469.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.74% (Net Income -98.8m / Total Assets 464.9m)
RoE = -11.76% (Net Income TTM -98.8m / Total Stockholder Equity 840.2m)
RoCE = -13.19% (EBIT -110.9m / Capital Employed (Equity 840.2m + L.T.Debt 0.0))
RoIC = -19.46% (negative operating profit) (NOPAT -87.6m / Invested Capital 450.1m)
WACC = 11.24% (E(2.57b)/V(2.57b) * Re(11.24%) + D(302k)/V(2.57b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.24% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 20.70%
[DCF] Fair Price = unknown (Cash Flow -65.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.32 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.40 | Chg30d=+4.76% | Revisions=+20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.47 | Chg30d=+7.84% | Revisions=+20% | Analysts=1
EPS current Year (2026-12-31): EPS=-1.82 | Chg30d=+5.93% | Revisions=+20% | GrowthEPS=+0.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.38 | Chg30d=+6.17% | Revisions=+20% | GrowthEPS=-30.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +20%